# Amgen Inc.  Share Price Target ‘$315.60’, now 1.9% Upside Potential

- Link: https://www.directorstalkinterviews.com/amgen-inc-share-price-target-315-60-now-1-9-upside-potential/4121187582
- Published: 2025-02-25T15:14:47+00:00
- Author: Charlotte Edwards

**Amgen Inc.** with ticker code (AMGN) now have 26 analysts in total covering the
stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges
between $389.00 and $195.00 suggesting an average analyst share price target price
of $315.60. (at the time of writing). Given that the stocks previous close was at
$309.72 and the analysts are correct then we can expect a percentage increase in
value of 1.9%. The 50 day MA is $277.29 while the 200 day moving average is $305.98.
The market capitalization for the company is 169.60B. The price for the stock stands
currently at: $315.71 USD

 The potential market cap would be $172,822,325,828 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 41.76, revenue per share of $62.24
and a 6.4% return on assets.

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures
and delivers various human therapeutics. It operates in human therapeutics segment.
The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab),
Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha(
evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb),
Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO(
blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (
adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene
laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras,
Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment
of serious illness in the areas of inflammation, oncology/hematology, bone health,
cardiovascular disease, nephrology and neuroscience.

Share on:
